Official UK procurement notice
NP47924 Cytokine Modulators · UK public procurement notice
Authority: The Common Services Agency (more commonly known as NHS National Services Scotland) (NSS) (NHS & healthcare)
What is being bought7 lots · detail below
Published requirement descriptionSupply of Cytokine Modulators to NHS Scotland.
CPV: Pharmaceutical products
How this framework works
From the published notice- Places
- up to 8 suppliers · 4 bids on the busiest of 7 lots (0.5 per place) · 8 appointed (full)
Lots and requirements (7)Procurement structure
7 lots · all with a published value · same evaluation weights on every lotLot #1EtanerceptAwardedRenewalPublished value£11,337,834
Supply of Etanercept to NHS Scotland.
The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of three (3) Framework Participants.
Lot #2Infliximab IVAwardedRenewalPublished value£5,584,117
Supply of Infliximab IV to NHS Scotland.
The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of five (5) Framework Participants.
Lot #3Infliximab SCAwardedRenewalPublished value£1,364,625
Supply of Infliximab SC to NHS Scotland.
The Authority intends to award this Lot as a single supplier framework per product line.
Lot #4Methotrexate syringes (25mg/1 ml concentration)AwardedRenewalPublished value£57,674
Supply of Methotrexate syringes (25mg/1 ml concentration) to NHS Scotland.
The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of three (3) Framework Participants.
Lot #5Methotrexate pens (25mg/1ml concentration)AwardedRenewalPublished value£57,473
Supply of Methotrexate pens (25mg/1ml concentration)to NHS Scotland.
The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of three (3) Framework Participants.
Lot #6Methotrexate pens (50mg/1 ml concentration)AwardedRenewalPublished value£4,459,687
Supply of Methotrexate pens (50mg/1 ml concentration) to NHS Scotland.
The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of three (3) Framework Participants.
Lot #7Methotrexate syringes (50mg/1ml concentration)AwardedRenewalPublished value£101,754
Supply of Methotrexate syringes (50mg/1ml concentration) to NHS Scotland.
The Authority intends to award this Lot as an unranked multi-supplier framework per product line to a maximum of three (3) Framework Participants.
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Published sub-criteria (2)
- API Sources: 5%
- price: 95%
Published award criteria (2)
- API Sources: 5
- Price: 95
- Technical & professional ability
(a) Potential Framework Participants must be able to demonstrate the existence of a valid and current UK Marketing Authorisation (PL, PLGB, or PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender.
(b) Potential Framework Participants and any sub-contractor(s) must possess valid certification of BS EN ISO 9001 or equivalent.
(c) All tendered Goods must comply with the MHRA best Practice Guidance on Labelling and Packaging and the National Patient Safety Agency ("NPSA") Guidelines on Packaging and Labelling on pack design.
(d) Potential Framework Participants are required to provide evidence that their organisation has taken steps to build their awareness of the climate change emergency and how they will respond.
Minimum: (a) Confirmation of existence of a valid and current UK Marketing Authorisation (PL, PLGB, PLPI number) that has been approved by the MHRA for all tendered Medicines at the date of submission of the tender should be included in the Qualification Envelope of the ITT under the Tech…
- Price carries 95 of 100 points: a 10% discount moves about 9.5 points. This one is won on the number: sharpen the price before polishing the prose.
- “NP47924 Cytokine Modulators” is a framework: the contest is a place on its panel, up to 8 suppliers, not a single contract.
Price arithmetic assumes straight proportional scoring; the tender pack may use another formula.
Procedure terms & legal framework
From the official record · publisher note attached- Procedure method
- Open procedure
- Legal basis
- CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Unspecified in notice
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use this agreement
- Not stated in the notice; call-off rights may be limited to the establishing authority
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- No (one-off requirement)
- First published
- 1 Nov 2024, 13:49 GMT
- Last source update
- 19 Mar 2025, 09:15 GMT
- Award evaluation window
- 2 Dec 2024 – …
- FTS notice number
2025/S 000-010054- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-04b34fFind a Tender
- Electronic trading
- e-invoicing allowed · electronic ordering · electronic payment
- Review procedure
The Authority will notify economic operators who submitted a tender or (where no deselection notification has previously been made) applied to be selected to tender, of its decision to award the framework agreement which notification will contain among other information, a summary of the reasons why the economic operators was unsuccessful. The notification will incorporate a ‘standstill period’ of a minimum of 10 clear calendar days (or a minimum of 15 if the communication method used is not electronic) between the date on which the Authority dispatches the notice(s) and the date on which the Authority proposes to conclude the relevant framework agreement. The bringing of court proceedings against the Authority during the standstill period will automatically continue the prohibition on entering into the framework agreement until the court proceedings are determined, discontinued, or disposed of, or the court, by interim order, brings to an end the prohibition. The remedies that may be awarded by the courts before the framework agreement has been entered into include the setting aside of the decision to award the framework agreement to the winning tenderer(s). The bringing of court proceedings against the Authority after the framework agreement has been entered into will not affect the framework agreement unless grounds for the imposition of special penalties under the Public Contracts (Scotland) Regulations 2015 can be established. Otherwise, the remedies that may be awarded by the courts where the framework agreement has been entered into are limited to the award of damages.
Publisher note: The estimated value(s) referred to in Section II.1.5 and within all Lots cover(s) the twenty four (24) month contract duration and the twenty four (24) month extension period of the framework agreement. (SC Ref:793130)
How it was run
Official notice- Appointment period ends
- 2 Dec 2024, 12:00 GMT
- Submission channel
- {"electronicSubmission"}
- Accepted languages
- en
- Bids opened
- 2 Dec 2024, 12:00 GMT
Timeline
2 Dec 2024 → 19 Mar 2025 · 3 dates- Admission / appointment period endsperiod end, not a bid countdown2 Dec 2024, 12:00 GMT
- Bids opened2 Dec 2024, 12:00 GMT
- Notice published19 Mar 2025, 09:15 GMT
Notice history
1 event · 2 releases on Find a Tender- Status changed to complete19 Mar 2025, 09:15 GMT
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast7 suppliers are admitted to this framework without individual award values or dates, see the supplier list below.
Contracts
Etanercept
- Signed
- 29 Jan 2025
- Value
- £1,700,000
- Status
- active
Infliximab IV
- Signed
- 29 Jan 2025
- Value
- £44,300,000
- Status
- active
Methotrexate pens (25mg/1ml concentration)
- Signed
- 29 Jan 2025
- Value
- £5,150,000
- Status
- active
Infliximab SC
- Signed
- 29 Jan 2025
- Value
- £4,200,000
- Status
- active
Methotrexate syringes (25mg/1 ml concentration)
- Signed
- 29 Jan 2025
- Value
- £577,000
- Status
- active
Methotrexate pens (50mg/1 ml concentration)
- Signed
- 29 Jan 2025
- Value
- £1,000
- Status
- active
Methotrexate syringes (50mg/1ml concentration)
- Signed
- 29 Jan 2025
- Value
- £15,000
- Status
- active
Bid statistics published by the authority
| Lot | Bids | SME | VCSE | Valid bid range |
|---|---|---|---|---|
| 1 · Etanercept | 3bids · 3 electronic | 0 | — | — |
| 2 · Infliximab IV | 4bids · 4 electronic | 0 | — | — |
| 3 · Infliximab SC | 1bids · 1 electronic | 0 | — | — |
| 4 · Methotrexate syringes (25mg/1 ml concentration) | 1bids · 1 electronic | 0 | — | — |
| 5 · Methotrexate pens (25mg/1ml concentration) | 1bids · 1 electronic | 0 | — | — |
| 6 · Methotrexate pens (50mg/1 ml concentration) | 1bids · 1 electronic | 0 | — | — |
| 7 · Methotrexate syringes (50mg/1ml concentration) | 1bids · 1 electronic | 0 | — | — |
Contracting authority & participating public bodies
Dispute resolution & review bodies
- Sheriff Court HouseReview body
Framework contractors & participating bidders
9 commercial parties on the notice- Accord Healthcare LtdFramework contractor
- Biogen Idec LtdFramework contractor
- Celltrion Healthcare United Kingdom LimitedFramework contractor
- Janssen Cilag LimitedFramework contractor
- Nordic Pharma LtdFramework contractor
- Pfizer LtdFramework contractor
- SandozFramework contractor
- Sandoz LtdFramework contractor
- medac Pharma LLPFramework contractor
Official documents & specifications
Official links; attachments are not copiedNo document links were published on the notice.